Trial Profile

Study of MP1032 for the treatment of patients with Duchenne muscular dystrophy

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 07 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MP 1032 (Primary) ; MP 1032 (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions

Most Recent Events

07 Jul 2023 New trial record
30 May 2023 According to a MetrioPharm Media Release, the company plans to initiate a Phase II clinical trial in DMD in 2024.
30 May 2023 According to a MetrioPharm Media Release, the company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for MP1032 for the treatment of Duchenne muscular dystrophy.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com